Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment

A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01599637

Enrollment

Registered

2012-05-16

Start date

2012-04-30

Completion date

2013-09-30

Last updated

2015-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Idiopathic Urticaria

Keywords

Chronic idiopathic urticaria, CIU, Xolair, IGE025, FcεRI, IgE

Brief summary

The study is designed to explore the mode of action for omalizumab therapy in patients with chronic idiopathic urticaria.

Interventions

DRUGIGE025

Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.

DRUGplacebo

Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamines at Baseline

Exclusion criteria

* Clearly defined underlying etiology for chronic urticarias other than CIU (main manifestation being physical urticaria). This includes the following urticarias: Acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact, as well as the following diseases as these diseases may have symptoms of urticaria or angioedema: Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer. * Previous treatment with omalizumab. * A history or presence of atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or other skin disease associated with itch. Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	Baseline through Day 85 post-treatment	Observed values and absolute change in FcεRI positive skin cells: dermis non-lesional and lesional. The primary variable for this study was the relative change from baseline in the high affinity IgE receptor (FcεRI) positive skin cells, based on skin biopsies collected from patients with CIU after 12 weeks of treatment.The values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2
Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	Baseline through Day 85 post-treatment	Observed values and absolute change in IgE positive skin cells: dermis non-lesional and lesional The primary variable for this study was the relative change from baseline in IgE positive skin cells, based on skin biopsies collected from patients with CIU after 12 weeks of treatment. The values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2

Secondary

Measure	Time frame	Description
Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Baseline to Day 85	The average number of cells derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2
Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Baseline through Day 85	—
Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Baseline through Day 85	Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry that provides a method for sorting a heterogeneous mixture of biological cells into two or more containers, one cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. (FACS) provides fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest. A wide range of fluorophores can be used as labels in flow cytometry. Fluorophores are typically attached to an antibody that recognizes a target feature on or in the cell; they may also be attached to a chemical entity with affinity for the cell membrane or another cellular structure. Each fluorophore has a characteristic peak excitation and emission wavelength.
Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Baseline through Day 85	Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry that provides a method for sorting a heterogeneous mixture of biological cells into two or more containers, one cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. (FACS) provides fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest. A wide range of fluorophores can be used as labels in flow cytometry. Fluorophores are typically attached to an antibody that recognizes a target feature on or in the cell; they may also be attached to a chemical entity with affinity for the cell membrane or another cellular structure. Each fluorophore has a characteristic peak excitation and emission wavelength.
Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Baseline	The # positive cell values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2
Serum Levels of Omalizumab	Baseline through Day 85	Serum concentrations (ng/mL) of omalizumab by visit after the administration of omalizumab 300 mg every 4 weeks
Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Baseline through Day 85	—
Mean (SD) Serum Total IgE % Change From Baseline by Visit	Baseline through Day 85	—
Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Baseline through Day 85	Correlation of primary endpoint with The UAS7 which is a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0-3 (0 = none to 3 = intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch. The daily UAS is the average of the morning and evening scores and the UAS7 is the sum of the daily UAS scores over 7 days.UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. If fewer than 7 but at least 4 daily values were non-missing, the remaining values were imputed to be the average. This is equivalent to multiplying the average of the non missing values by 7. UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. A higher score indicates worse disease.
Mean (SD) Serum Free IgE % Change From Baseline by Visit	Baseline through Day 85	—
Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Baseline through Day 140	—
Change From Baseline in Urticaria Activity Score (UAS7)	Baseline, Day 85	Efficacy was assessed by the urticaria activity score (UAS). UAS was completed each morning and evening on a daily basis to record patient symptoms of itch and hives via an electronic diary. The UAS is a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0-3 (0 = none to 3 = intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch. The daily UAS is the average of the morning and evening scores and the UAS7 is the sum of the daily UAS scores over 7 days.UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. If fewer than 7 but at least 4 daily values were non-missing, the remaining values were imputed to be the average. This is equivalent to multiplying the average of the non missing values by 7. UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. A higher score indicates worse disease. A negative change score (Week 12 score minus Baseline score) indicates improvement.
Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Baseline, Day 85	The investigator or the person he or she designated and the patient provided scoring of the patient's global assessment of symptoms (urticaria lesions (hives) and pruritus) reflective of the patient's condition over the 12 hours prior to the visit (0 = no symptoms, 1 = mild, 2 = moderate 3 = severe
Percentage of Angioedema-free Days Weeks 4 Through 12 by Treatment	Day 29 to Day 85	—
Change From Baseline in Dermatology Life Quality Index (DLQI) by Treatment	Baseline through Day 85	The DLQI is a 10-item dermatology-specific health-related quality of life measure. Patients rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives. An overall score was calculated as well as for the following domains: Symptoms and Feelings, Daily Activities, Leisure, Work and School, Personal Relationships, Treatment.Negative score shows positive efficacy. Meaning of DLQI Scores 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30.
Skindex-29 by Treatment	Baseline and Day 85	The Skindex-29 is a validated 29-item instrument to measure the effects of skin disease on patients' quality of life.Results are reported as 3 scale scores (functioning, emotions and symptoms) and a composite score (average scale score). The domain scores and the overall score are expressed on a 100-point scale, with higher scores indicating a lower level of quality of life. The cuttoff values for each category are noted below. Symtoms; 39 mild, 42 moderate,52 severe. Emotions; 24 mild, 35 moderate, 39 severe. Functioning: 21 mild, 32 moderate, 37 severe. Overal Score: 25 mild, 32 moderate, 44 severe.
Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment	Baseline and Day 85	The Cu-Q2OL is a 23-item CIU-specific health-related quality of life questionnaire. Patients rated their CIU symptoms and the impact of their CIU on various aspects of their lives. An overall score was calculated as well for the following domains: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. Zero is the minmum score and 100 the maximum score. The higher score correlates to more disease activity.
Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Baseline through Day 85	—
Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Baseline through Day 85	Correlation of primary endpoint with The UAS7 which is a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0-3 (0 = none to 3 = intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch. The daily UAS is the average of the morning and evening scores and the UAS7 is the sum of the daily UAS scores over 7 days.UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. If fewer than 7 but at least 4 daily values were non-missing, the remaining values were imputed to be the average. This is equivalent to multiplying the average of the non missing values by 7. UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. A higher score indicates worse disease.

Countries

Germany

Participant flow

Participants by arm

Arm	Count
IGE025 IGE025 administered subcutaneously every 4 weeks at the study center	20
Placebo to IGE025 Placebo administered subcutaneously every 4 weeks at the study center.	10
Healthy Volunteers Healthy volunteer data was collected at baseline only. These healthy volunteers did not receive any test treatment. The data collected from these individuals was used to provide a reference to help characterize the levels of skin biopsy markers and were used in the descriptive analyses but not formally compared with the corresponding levels in the treated subjects	10
Total	40

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	administrative problems	0	2	0
Overall Study	Adverse Event	1	0	0

Baseline characteristics

Characteristic	IGE025	Placebo to IGE025	Healthy Volunteers	Total
Age, Continuous	37.5 years STANDARD_DEVIATION 11.02	41.1 years STANDARD_DEVIATION 7.96	36.4 years STANDARD_DEVIATION 9.74	38.7 years STANDARD_DEVIATION 10.11
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	20 Participants	10 Participants	10 Participants	40 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Sex: Female, Male Female	18 Participants	8 Participants	10 Participants	36 Participants
Sex: Female, Male Male	2 Participants	2 Participants	0 Participants	4 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	17 / 20	6 / 10
serious Total, serious adverse events	0 / 20	2 / 10

Outcome results

Primary

Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin

Observed values and absolute change in FcεRI positive skin cells: dermis non-lesional and lesional. The primary variable for this study was the relative change from baseline in the high affinity IgE receptor (FcεRI) positive skin cells, based on skin biopsies collected from patients with CIU after 12 weeks of treatment.The values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2

Time frame: Baseline through Day 85 post-treatment

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis. Patients with both baseline and week 12 data were included in this analysis

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skin cells: dermis lesional D1 (n=19,8)	18.14 FcεRI positive skin cells	Standard Deviation 7.08
IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skin cells: dermis lesional d85 (n=10,7)	13.40 FcεRI positive skin cells	Standard Deviation 5.88
IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skin cells:dermis lesional Chge(n=10,6)	-5.42 FcεRI positive skin cells	Standard Deviation 7.42
IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skincells:dermis nonlesional D1(n=19,10)	18.91 FcεRI positive skin cells	Standard Deviation 9.42
IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skincells:dermis nonlesional D85(n=18,8)	14.72 FcεRI positive skin cells	Standard Deviation 7.56
IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skincells:dermis nonlesional Chg(n=17,8)	-5.40 FcεRI positive skin cells	Standard Deviation 9.06
Placebo IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skincells:dermis nonlesional D85(n=18,8)	20.81 FcεRI positive skin cells	Standard Deviation 7.3
Placebo IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skin cells: dermis lesional D1 (n=19,8)	15.17 FcεRI positive skin cells	Standard Deviation 3.11
Placebo IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skincells:dermis nonlesional D1(n=19,10)	20.48 FcεRI positive skin cells	Standard Deviation 5.54
Placebo IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skin cells: dermis lesional d85 (n=10,7)	20.19 FcεRI positive skin cells	Standard Deviation 8.76
Placebo IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skincells:dermis nonlesional Chg(n=17,8)	-0.07 FcεRI positive skin cells	Standard Deviation 9.33
Placebo IGE025	Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	FcεRI +ve skin cells:dermis lesional Chge(n=10,6)	3.69 FcεRI positive skin cells	Standard Deviation 10.58

Primary

Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin

Observed values and absolute change in IgE positive skin cells: dermis non-lesional and lesional The primary variable for this study was the relative change from baseline in IgE positive skin cells, based on skin biopsies collected from patients with CIU after 12 weeks of treatment. The values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2

Time frame: Baseline through Day 85 post-treatment

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells, lesional D1 (n=19,8)	12.93 IgE positive skin cells	Standard Deviation 8.61
IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells, lesional D85 (n=10,7)	6.73 IgE positive skin cells	Standard Deviation 7.9
IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells, lesional chg(n=10.6)	-5.69 IgE positive skin cells	Standard Deviation 10.96
IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells,non-lesional D1 (n=19,10)	13.82 IgE positive skin cells	Standard Deviation 10.21
IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells,non-lesional D85 (n=18,8)	9.80 IgE positive skin cells	Standard Deviation 11.66
IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells,non-lesional Chng (n=17,8)	-4.87 IgE positive skin cells	Standard Deviation 9.83
Placebo IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells,non-lesional D85 (n=18,8)	18.30 IgE positive skin cells	Standard Deviation 7.51
Placebo IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells, lesional D1 (n=19,8)	15.23 IgE positive skin cells	Standard Deviation 15.71
Placebo IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells,non-lesional D1 (n=19,10)	16.59 IgE positive skin cells	Standard Deviation 9.35
Placebo IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells, lesional D85 (n=10,7)	12.47 IgE positive skin cells	Standard Deviation 6.54
Placebo IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells,non-lesional Chng (n=17,8)	-0.84 IgE positive skin cells	Standard Deviation 6.18
Placebo IGE025	Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin	IgE positive cells, lesional chg(n=10.6)	-3.95 IgE positive skin cells	Standard Deviation 20.76

Secondary

Change From Baseline in Dermatology Life Quality Index (DLQI) by Treatment

The DLQI is a 10-item dermatology-specific health-related quality of life measure. Patients rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives. An overall score was calculated as well as for the following domains: Symptoms and Feelings, Daily Activities, Leisure, Work and School, Personal Relationships, Treatment.Negative score shows positive efficacy. Meaning of DLQI Scores 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30.

Time frame: Baseline through Day 85

Population: Efficacy analysis set which included all randomized patients who received at least one dose of study drug and had post-randomization efficacy data

Arm	Measure	Value (MEAN)	Dispersion
IGE025	Change From Baseline in Dermatology Life Quality Index (DLQI) by Treatment	-10.19 Score	Standard Deviation 8.159
Placebo IGE025	Change From Baseline in Dermatology Life Quality Index (DLQI) by Treatment	-3.13 Score	Standard Deviation 7.18

Secondary

Change From Baseline in Urticaria Activity Score (UAS7)

Efficacy was assessed by the urticaria activity score (UAS). UAS was completed each morning and evening on a daily basis to record patient symptoms of itch and hives via an electronic diary. The UAS is a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0-3 (0 = none to 3 = intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch. The daily UAS is the average of the morning and evening scores and the UAS7 is the sum of the daily UAS scores over 7 days.UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. If fewer than 7 but at least 4 daily values were non-missing, the remaining values were imputed to be the average. This is equivalent to multiplying the average of the non missing values by 7. UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. A higher score indicates worse disease. A negative change score (Week 12 score minus Baseline score) indicates improvement.

Time frame: Baseline, Day 85

Population: Efficacy analysis set which included all randomized patients who received at least one dose of study drug and had post-randomization efficacy data. If the Week 12 value was missing, it was imputed as the last available UAS7 value (LOCF).

Arm	Measure	Value (MEAN)	Dispersion
IGE025	Change From Baseline in Urticaria Activity Score (UAS7)	-23.1 units on a scale	Standard Deviation 12.94
Placebo IGE025	Change From Baseline in Urticaria Activity Score (UAS7)	-8.1 units on a scale	Standard Deviation 14.45

Secondary

Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment

The Cu-Q2OL is a 23-item CIU-specific health-related quality of life questionnaire. Patients rated their CIU symptoms and the impact of their CIU on various aspects of their lives. An overall score was calculated as well for the following domains: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. Zero is the minmum score and 100 the maximum score. The higher score correlates to more disease activity.

Time frame: Baseline and Day 85

Population: Efficacy analysis set which included all randomized patients who received at least one dose of study drug and had post-randomization efficacy data

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment	Baseline (n=16,8)	53.71 score	Standard Deviation 19.881
IGE025	Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment	Day 85 (n=17,8)	14.51 score	Standard Deviation 22.319
Placebo IGE025	Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment	Baseline (n=16,8)	59.24 score	Standard Deviation 15.35
Placebo IGE025	Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment	Day 85 (n=17,8)	53.53 score	Standard Deviation 29.817

Secondary

Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set

The # positive cell values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2

Time frame: Baseline

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Cd 3 Dermis (n=10,29)	10.1600 # positive cells	Standard Deviation 9.00311
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Giemsa Epidermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 8 Epidermis (n=10,29)	0.0600 # positive cells	Standard Deviation 0.13499
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Giemsa Dermis (n=10,29)	4.8000 # positive cells	Standard Deviation 5.62929
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD11c All skin layers (n=20,58)	7.9000 # positive cells	Standard Deviation 9.45983
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Giemsa All Skin Layers (n=20,58)	2.4000 # positive cells	Standard Deviation 4.59061
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 8 Dermis (n=10,29)	5.9083 # positive cells	Standard Deviation 4.07998
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Haematoxylin + Eosin Epidermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 3 All Skin Layers (n=20,58)	5.1600 # positive cells	Standard Deviation 8.04634
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Haematoxylin + Eosin Dermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 8 All Skin Layers (n=20,58)	2.9842 # positive cells	Standard Deviation 4.11029
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Haematoxylin + Eosin All Skin Layers (n=20,58)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD11c Dermis (n=10,29)	14.6400 # positive cells	Standard Deviation 9.31083
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE Epidermis (n=10,29)	0.0800 # positive cells	Standard Deviation 0.13984
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 117 Epidermis (n=10,29)	10.1600 # positive cells	Standard Deviation 3.80386
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE Dermis (n=10,29)	8.7600 # positive cells	Standard Deviation 5.92231
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 4 Epidermis (n=10,29)	1.0250 # positive cells	Standard Deviation 1.75804
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE All Skin layers (n=20,58)	4.4200 # positive cells	Standard Deviation 6.03739
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 117 Dermis (n=10,29)	8.2200 # positive cells	Standard Deviation 2.44849
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + CD 11c Epidermis (n=10,28)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 3 Epidermis (n=10,29)	0.1600 # positive cells	Standard Deviation 0.26331
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + CD 11c Dermis (n=10,29)	0.9150 # positive cells	Standard Deviation 1.29401
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 117 All Skin Layers (n=20,58)	9.1900 # positive cells	Standard Deviation 3.26865
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE+CD 11c All Layers (n=20,57)	0.4575 # positive cells	Standard Deviation 1.00672
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 4 Dermis (n=10,29)	15.7750 # positive cells	Standard Deviation 10.06565
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + Tryptase Epidermis (n=10,28)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Fc epsilon receptor I Epidermis (n=10,29)	4.9800 # positive cells	Standard Deviation 2.02309
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + Tryptase Dermis (n=10,29)	1.3000 # positive cells	Standard Deviation 1.01215
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD11c Epidermis ( n= 10,29)	1.1600 # positive cells	Standard Deviation 1.13058
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + Tryptase All Skin Layers (n=20,57)	0.6500 # positive cells	Standard Deviation 0.96437
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Fc epsilon receptor I Dermis (n=10,29)	14.2000 # positive cells	Standard Deviation 6.76133
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Tryptase Epidermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 4 All Skin Layers (n=20,58)	8.4000 # positive cells	Standard Deviation 10.33004
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Tryptase Dermis (n=10,29)	6.6400 # positive cells	Standard Deviation 3.53371
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Tryptase All Skin Layers (n=20,58)	3.3200 # positive cells	Standard Deviation 4.18539
IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Fc epsilon receptor I All Skin Layers (n=20,58)	9.5900 # positive cells	Standard Deviation 6.77968
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Tryptase All Skin Layers (n=20,58)	3.3871 # positive cells	Standard Deviation 4.26704
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD11c Epidermis ( n= 10,29)	1.1241 # positive cells	Standard Deviation 0.92944
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD11c Dermis (n=10,29)	19.6207 # positive cells	Standard Deviation 9.4226
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD11c All skin layers (n=20,58)	10.3724 # positive cells	Standard Deviation 11.44855
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 3 Epidermis (n=10,29)	0.4759 # positive cells	Standard Deviation 0.82046
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Cd 3 Dermis (n=10,29)	10.8276 # positive cells	Standard Deviation 6.11385
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 3 All Skin Layers (n=20,58)	5.6517 # positive cells	Standard Deviation 6.77879
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 4 Epidermis (n=10,29)	1.0207 # positive cells	Standard Deviation 1.26297
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 4 Dermis (n=10,29)	17.7000 # positive cells	Standard Deviation 9.72481
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 4 All Skin Layers (n=20,58)	9.3603 # positive cells	Standard Deviation 10.86324
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 8 Epidermis (n=10,29)	0.2138 # positive cells	Standard Deviation 0.34197
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 8 Dermis (n=10,29)	6.0322 # positive cells	Standard Deviation 3.43255
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 8 All Skin Layers (n=20,58)	3.1230 # positive cells	Standard Deviation 3.80226
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 117 Epidermis (n=10,29)	9.9931 # positive cells	Standard Deviation 4.85502
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 117 Dermis (n=10,29)	10.4241 # positive cells	Standard Deviation 5.56025
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	CD 117 All Skin Layers (n=20,58)	10.2086 # positive cells	Standard Deviation 5.17814
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Fc epsilon receptor I Epidermis (n=10,29)	6.0776 # positive cells	Standard Deviation 3.12906
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Fc epsilon receptor I Dermis (n=10,29)	19.4500 # positive cells	Standard Deviation 8.21582
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Fc epsilon receptor I All Skin Layers (n=20,58)	12.7638 # positive cells	Standard Deviation 9.13548
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Giemsa Epidermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Giemsa Dermis (n=10,29)	6.8690 # positive cells	Standard Deviation 6.19228
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Giemsa All Skin Layers (n=20,58)	3.4345 # positive cells	Standard Deviation 5.55324
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Haematoxylin + Eosin Epidermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Haematoxylin + Eosin Dermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Haematoxylin + Eosin All Skin Layers (n=20,58)	0.0000 # positive cells	Standard Deviation 0
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE Epidermis (n=10,29)	1.0603 # positive cells	Standard Deviation 2.30385
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE Dermis (n=10,29)	14.7776 # positive cells	Standard Deviation 9.84503
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE All Skin layers (n=20,58)	7.9190 # positive cells	Standard Deviation 9.9038
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + CD 11c Epidermis (n=10,28)	0.0357 # positive cells	Standard Deviation 0.12237
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + CD 11c Dermis (n=10,29)	1.0115 # positive cells	Standard Deviation 1.0529
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE+CD 11c All Layers (n=20,57)	0.5322 # positive cells	Standard Deviation 0.89651
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + Tryptase Epidermis (n=10,28)	0.0000 # positive cells	Standard Deviation 0
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + Tryptase Dermis (n=10,29)	0.8713 # positive cells	Standard Deviation 0.79919
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	IgE + Tryptase All Skin Layers (n=20,57)	0.4433 # positive cells	Standard Deviation 0.71586
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Tryptase Epidermis (n=10,29)	0.0000 # positive cells	Standard Deviation 0
Placebo IGE025	Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set	Tryptase Dermis (n=10,29)	6.7741 # positive cells	Standard Deviation 3.64713

Secondary

Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status

Correlation of primary endpoint with The UAS7 which is a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0-3 (0 = none to 3 = intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch. The daily UAS is the average of the morning and evening scores and the UAS7 is the sum of the daily UAS scores over 7 days.UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. If fewer than 7 but at least 4 daily values were non-missing, the remaining values were imputed to be the average. This is equivalent to multiplying the average of the non missing values by 7. UAS7 score: The sum of the daily UAS scores over 7 days. Range: 0-42. A higher score indicates worse disease.

Time frame: Baseline through Day 85

Population: Efficacy analysis set: Includes all randomized patients who received at least one dose of study drug and have post-randomization efficacy data.

Arm	Measure	Group	Value (NUMBER)
IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, lesional	0.4841 correlation coefficient
IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, non-lesional	0.2759 correlation coefficient
IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, lesional	0.2190 correlation coefficient
IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, non-lesional	0.1574 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, non-lesional	-0.2310 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, lesional	-0.0952 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, lesional	-0.1142 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, non-lesional	0.4947 correlation coefficient

Secondary

Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status

Time frame: Baseline through Day 85

Population: Efficacy analysis set: Includes all randomized patients who received at least one dose of study drug and have post-randomization efficacy data.

Arm	Measure	Group	Value (NUMBER)
IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, lesional	0.3305 correlation coefficient
IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, non-lesional	0.2785 correlation coefficient
IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, non-lesional	0.0644 correlation coefficient
IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, lesional	0.0021 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, non-lesional	0.1563 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, lesional	-0.1889 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Dermis, non-lesional	0.5057 correlation coefficient
Placebo IGE025	Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status	Epidermis, lesional	0.0101 correlation coefficient

Secondary

Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment

The investigator or the person he or she designated and the patient provided scoring of the patient's global assessment of symptoms (urticaria lesions (hives) and pruritus) reflective of the patient's condition over the 12 hours prior to the visit (0 = no symptoms, 1 = mild, 2 = moderate 3 = severe

Time frame: Baseline, Day 85

Population: Efficacy analysis set which included all randomized patients who received at least one dose of study drug and had post-randomization efficacy data

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Physicians Baseline (n=17,9)	2.0 score	Standard Deviation 0.87
IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Physicians Week 12, (day 85) (n=17,8)	0.8 score	Standard Deviation 1.01
IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Patients Baseline (n=17,9)	2.4 score	Standard Deviation 0.87
IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Patients Week 12, (day 85) (n=17,8)	0.9 score	Standard Deviation 1.05
Placebo IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Patients Week 12, (day 85) (n=17,8)	1.9 score	Standard Deviation 0.99
Placebo IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Physicians Baseline (n=17,9)	2.2 score	Standard Deviation 0.83
Placebo IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Patients Baseline (n=17,9)	2.4 score	Standard Deviation 0.53
Placebo IGE025	Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment	Physicians Week 12, (day 85) (n=17,8)	2.0 score	Standard Deviation 1.31

Secondary

Mean (SD) Serum Free IgE % Change From Baseline by Visit

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 8 % Change (n=20,10)	-96.446 % change	Standard Deviation 2.0162
IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 57 % Change (n=18,8)	-94.460 % change	Standard Deviation 3.0681
IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 29 % Change (n=19,9)	-93.363 % change	Standard Deviation 3.5975
IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 85 % Change (n=16,8)	-94.750 % change	Standard Deviation 3.42
IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 2 % Change (n=19,9)	-96.166 % change	Standard Deviation 2.9216
Placebo IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 85 % Change (n=16,8)	-61.906 % change	Standard Deviation 17.7819
Placebo IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 2 % Change (n=19,9)	-60.475 % change	Standard Deviation 17.933
Placebo IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 8 % Change (n=20,10)	-60.804 % change	Standard Deviation 15.8379
Placebo IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 29 % Change (n=19,9)	-61.456 % change	Standard Deviation 17.234
Placebo IGE025	Mean (SD) Serum Free IgE % Change From Baseline by Visit	Day 57 % Change (n=18,8)	-61.270 % change	Standard Deviation 18.6447

Secondary

Mean (SD) Serum Free IgE Concentration From Baseline by Visit

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 57 Mean (n=19,8)	38.502 ng/mL	Standard Deviation 39.5567
IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 1 Mean (n=20,10)	1037 ng/mL	Standard Deviation 2474
IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 29 Mean (n=20,9)	41.506 ng/mL	Standard Deviation 40.5322
IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 2 Mean (n= 20,9)	26.8 ng/mL	Standard Deviation 34.27
IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 85 Mean (n=17,8)	35.776 ng/mL	Standard Deviation 41.5426
IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 8 Mean (n=20,10)	24.306 ng/mL	Standard Deviation 29.7698
Placebo IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 85 Mean (n=17,8)	120.978 ng/mL	Standard Deviation 50.6692
Placebo IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 29 Mean (n=20,9)	107.881 ng/mL	Standard Deviation 60.1708
Placebo IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 57 Mean (n=19,8)	122.318 ng/mL	Standard Deviation 51.1087
Placebo IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 8 Mean (n=20,10)	112.169 ng/mL	Standard Deviation 58.6525
Placebo IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 1 Mean (n=20,10)	442 ng/mL	Standard Deviation 580.69
Placebo IGE025	Mean (SD) Serum Free IgE Concentration From Baseline by Visit	Day 2 Mean (n= 20,9)	111.5 ng/mL	Standard Deviation 60.75

Secondary

Mean (SD) Serum Total IgE % Change From Baseline by Visit

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 8 % Change (n=19,10)	174.7 Percent Change from Baseline	Standard Deviation 84.93
IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 57 % Change (n=18,8)	247.8 Percent Change from Baseline	Standard Deviation 134.1
IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 29 % Change (n=19,9)	247.2 Percent Change from Baseline	Standard Deviation 121.81
IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 85 % Change (n=16,8)	244.8 Percent Change from Baseline	Standard Deviation 138.28
IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 2 % Change (n=19,10)	27.1 Percent Change from Baseline	Standard Deviation 20.08
Placebo IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 85 % Change (n=16,8)	-6.9 Percent Change from Baseline	Standard Deviation 24.1
Placebo IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 2 % Change (n=19,10)	0.2 Percent Change from Baseline	Standard Deviation 5.13
Placebo IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 8 % Change (n=19,10)	-1.5 Percent Change from Baseline	Standard Deviation 9.13
Placebo IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 29 % Change (n=19,9)	-4.0 Percent Change from Baseline	Standard Deviation 12.17
Placebo IGE025	Mean (SD) Serum Total IgE % Change From Baseline by Visit	Day 57 % Change (n=18,8)	-4.4 Percent Change from Baseline	Standard Deviation 18.59

Secondary

Mean (SD) Serum Total IgE Concentration From Baseline by Visit

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 2 Mean (20,10)	1152 ng/mL	Standard Deviation 2539
IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 29 Mean (n=20,9)	2160 ng/mL	Standard Deviation 2688
IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 1 Mean (n=20,10)	1037 ng/mL	Standard Deviation 2474
IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 57 Mean (n=19,8)	2430 ng/mL	Standard Deviation 3343
IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 8 Mean (n=20,10)	1970 ng/mL	Standard Deviation 2992
IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 85 Mean (n=17,8)	2222 ng/mL	Standard Deviation 2931
Placebo IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 85 Mean (n=17,8)	475 ng/mL	Standard Deviation 616.8
Placebo IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 1 Mean (n=20,10)	442 ng/mL	Standard Deviation 580.7
Placebo IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 2 Mean (20,10)	447 ng/mL	Standard Deviation 587.5
Placebo IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 8 Mean (n=20,10)	449 ng/mL	Standard Deviation 593.1
Placebo IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 29 Mean (n=20,9)	462 ng/mL	Standard Deviation 628.7
Placebo IGE025	Mean (SD) Serum Total IgE Concentration From Baseline by Visit	Day 57 Mean (n=19,8)	490 ng/mL	Standard Deviation 648

Secondary

Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit

The average number of cells derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2

Time frame: Baseline to Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis. Day 29 was an optional sampling time point in this paramter. The values are average of cell numbers derived from counting 5 consecutive microscopic fields. Area counted is 5x 0.196 mm2

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D8 (n=19,10) Change	0.42 # positive cells	Standard Deviation 7.613
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 29(n=5,0 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D29 (n=4,0)	15.63 # positive cells	Standard Deviation 10.636
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 29 (n=4,0)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D29 (n=4,0) Change	0.93 # positive cells	Standard Deviation 15.472
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 140 (n=16,7) Chg	1.27 # positive cells	Standard Deviation 3.599
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 8 (n=18,10 ) Chge	-1.33 # positive cells	Standard Deviation 5.141
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 8 (n=19,10)	0.49 # positive cells	Standard Deviation 0.754
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 140(n=6,5 )	7.57 # positive cells	Standard Deviation 2.589
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 8 (n=18,10) Change	0.14 # positive cells	Standard Deviation 0.636
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 140(n=18,8)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 29 (n=4,0)	0.32 # positive cells	Standard Deviation 0.367
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Baseline (n=19,8)	6.08 # positive cells	Standard Deviation 3.764
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 29 (n=4,0) Change	0.07 # positive cells	Standard Deviation 0.094
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 29 (n=4,0 )	3.88 # positive cells	Standard Deviation 1.876
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 85 (n=18,8)	0.47 # positive cells	Standard Deviation 0.66
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 29 (n=4,0) Chg	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 85 (n=17,8) Change	0.14 # positive cells	Standard Deviation 0.438
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 8 (n=11,10) Change	2.07 # positive cells	Standard Deviation 6.576
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 140(n=17,8) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 29 (n=5,0)	13.08 # positive cells	Standard Deviation 7.275
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 29(n=5,0 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional day 29 (n=5,0) Change	0.78 # positive cells	Standard Deviation 10.054
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Baseline (n=19,8)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 85 (n=10,7)	11.01 # positive cells	Standard Deviation 3.615
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 140 (n=17,7)	0.02 # positive cells	Standard Deviation 0.097
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 85 (n=10,6) Change	0.46 # positive cells	Standard Deviation 5.775
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Baseline (n=19,10)	9.47 # positive cells	Standard Deviation 5.07
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day140(n=16,7) Chg	0.03 # positive cells	Standard Deviation 0.1
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 140(n=6,4) Change	-0.61 # positive cells	Standard Deviation 1.281
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 29(n=4,0 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 8 (n=18,10) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epdiermis non lesional Day 85(n=18,8) Change	-0.31 # positive cells	Standard Deviation 2.239
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 85(n=10,6 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Baseline(n=19,10)	16.81 # positive cells	Standard Deviation 6.868
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 8 (n=11,8) Chg	0.31 # positive cells	Standard Deviation 1.093
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 140(n=17,7)	0.81 # positive cells	Standard Deviation 0.742
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 140 (n=16,7 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 140(n=16,7) Change	-0.07 # positive cells	Standard Deviation 1.283
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 8 (n=11,8) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Baseline(n=19,8)	0.95 # positive cells	Standard Deviation 1.066
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 85(n=10,5 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 8(n=11,10)	0.63 # positive cells	Standard Deviation 0.725
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 29 (n=5,0)	0.12 # positive cells	Standard Deviation 0.268
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 8(n=19,10)	17.80 # positive cells	Standard Deviation 8.144
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 29 (n=4,0) Chg	0.67 # positive cells	Standard Deviation 4.816
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 8(n=18,10) Change	1.21 # positive cells	Standard Deviation 9.816
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 85(n=10,7)	10.68 # positive cells	Standard Deviation 6.16
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Baseline(n=19,8 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 85 (n=17,8) Change	-0.01 # positive cells	Standard Deviation 5.75
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 29 (n=5,0) Chg	0.08 # positive cells	Standard Deviation 0.179
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 140(n=17,7)	12.05 # positive cells	Standard Deviation 4.212
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 29 (n=4,0 ) Chge	-1.62 # positive cells	Standard Deviation 1.811
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 140 (n=16,7) Change	0.69 # positive cells	Standard Deviation 5.439
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Baseline(n=19,8)	9.00 # positive cells	Standard Deviation 4.57
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 8(n=11,10)	10.15 # positive cells	Standard Deviation 6.629
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 8(n=11,10 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 8(n=11,8) Change	0.60 # positive cells	Standard Deviation 4.374
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 85 (n=18,8)	7.66 # positive cells	Standard Deviation 4.076
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 29(n=5,0)	12.42 # positive cells	Standard Deviation 5.175
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 8(n=11,8 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 29(n=5,0) Change	5.39 # positive cells	Standard Deviation 5.412
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 85(n=10,7)	11.07 # positive cells	Standard Deviation 6.023
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 29(n=5,0 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 29(n=4,0)	15.58 # positive cells	Standard Deviation 5.07
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 29(n=5,0 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 29(n=4,0) Change	-0.88 # positive cells	Standard Deviation 1.928
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 85 (n=10,6)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 85(n=18,8) Change	19.33 # positive cells	Standard Deviation 7.741
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 29(n=5,0 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 85(n=17,8) Change	1.94 # positive cells	Standard Deviation 10.126
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 140(n=6,5 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 140(n=17,7)	21.14 # positive cells	Standard Deviation 11.3
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 29 (n=4,0) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 140(n=16,7) Change	3.36 # positive cells	Standard Deviation 11.994
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 85(n=10,7)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional baseline(n=19,8)	14.28 # positive cells	Standard Deviation 5.351
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 85(n=10,6 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 8(n=11,10)	17.84 # positive cells	Standard Deviation 10.403
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 85 (n=10,5) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 8(n=11,8) Change	2.86 # positive cells	Standard Deviation 7.576
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 85(n=10,6) Chg	-0.02 # positive cells	Standard Deviation 0.063
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 29(n=5,0)	17.12 # positive cells	Standard Deviation 8.146
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Baseline (n=19,10)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 85(n=10,5 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epdiermis lesional Day 29(n=5,0) Change	0.12 # positive cells	Standard Deviation 1.726
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 85 (n=17,8) Chg	0.54 # positive cells	Standard Deviation 3.753
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 140 (n=7,5)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 8(n=19,10)	0.40 # positive cells	Standard Deviation 0.593
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 29 (n=4,0)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 8(n=18,10) Change	0.24 # positive cells	Standard Deviation 0.55
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 140(n=6,5 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 29(n=4,0)	0.39 # positive cells	Standard Deviation 0.347
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 8 (n=19,10)	0.02 # positive cells	Standard Deviation 0.092
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 29(n=4,0) Change	-0.21 # positive cells	Standard Deviation 0.448
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 140 (n=7,4) Chg	-0.03 # positive cells	Standard Deviation 0.076
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 85(n=18,8)	0.22 # positive cells	Standard Deviation 0.361
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 140(n=6,5 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 85 (n=17,8)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 140(n=17,7)	0.16 # positive cells	Standard Deviation 0.215
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 140(n=6,4 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 140(n=16,7) Change	-0.04 # positive cells	Standard Deviation 0.344
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 29(n=5,0 ) Chge	2.57 # positive cells	Standard Deviation 12.812
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Baseline(n=19,8)	0.34 # positive cells	Standard Deviation 0.644
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Baseline(n=19,10 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 8(n=18,10) Chg	0.02 # positive cells	Standard Deviation 0.094
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 85(n=10,7)	0.14 # positive cells	Standard Deviation 0.313
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Baseline (n=19,10)	6.55 # positive cells	Standard Deviation 3.988
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 85(n=10,6) Change	-0.01 # positive cells	Standard Deviation 0.356
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 140(n=6,4 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 140(n=6,5)	0.03 # positive cells	Standard Deviation 0.082
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 8(n=19,10 )	0.01 # positive cells	Standard Deviation 0.046
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 140(n=6,4) Change	-0.53 # positive cells	Standard Deviation 1.129
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 8 (n=19,10)	7.14 # positive cells	Standard Deviation 4.479
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Baseline(n=19,10)	5.74 # positive cells	Standard Deviation 3.278
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 29(n=5,0) Chg	3.80 # positive cells	Standard Deviation 3.023
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8(n=19,10)	7.10 # positive cells	Standard Deviation 5.02
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 140 (n=18,10 )	6.69 # positive cells	Standard Deviation 5.409
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8 (n=18,10) Change	1.19 # positive cells	Standard Deviation 4.798
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 85(n=10,7)	6.76 # positive cells	Standard Deviation 3.082
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=4,0)	8.45 # positive cells	Standard Deviation 5.369
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 85(n=10,6 )	5.96 # positive cells	Standard Deviation 2.589
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8(n=11,10)	7.55 # positive cells	Standard Deviation 4.953
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D140 (n=6,5)	0.53 # positive cells	Standard Deviation 0.555
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8(n=11,8) Change	1.02 # positive cells	Standard Deviation 5.174
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Baseline (n=19,10 )	6.91 # positive cells	Standard Deviation 4.751
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=5,0)	10.14 # positive cells	Standard Deviation 6.133
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D140 (n=6,5) Change	0.12 # positive cells	Standard Deviation 0.599
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=5,0) Change	2.48 # positive cells	Standard Deviation 5.639
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 85 (n=10,5 ) Chge	-1.56 # positive cells	Standard Deviation 7.155
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85(n=10,7)	7.19 # positive cells	Standard Deviation 3.022
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional baseline (n=19,10)	17.86 # positive cells	Standard Deviation 7.322
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85(n=10,6) Change	0.98 # positive cells	Standard Deviation 3.556
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 8 (n=19,10 )	5.51 # positive cells	Standard Deviation 4.142
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=6,5)	7.73 # positive cells	Standard Deviation 6.774
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D8 (n=19,10)	18.33 # positive cells	Standard Deviation 8.971
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=6,4)	1.87 # positive cells	Standard Deviation 7.44
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 140 (n=17,7)	7.77 # positive cells	Standard Deviation 4.296
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 8 (n=19,10)	10.29 # positive cells	Standard Deviation 4.555
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 8 (n=19,10)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional day 8(n=19,10 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 85 (n=18,8)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 8 (n=11,10)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 8(n=11,8) Change	0.30 # positive cells	Standard Deviation 0.534
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 8(n=11,8) Change	2.58 # positive cells	Standard Deviation 4.315
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 85(n=10,6) Change	2.11 # positive cells	Standard Deviation 5.917
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 140(n=6,5)	10.92 # positive cells	Standard Deviation 6.704
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 140(n=6,4) Change	5.12 # positive cells	Standard Deviation 6.41
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Baseline (n=19,10)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 85 (n=18,8 )	4.75 # positive cells	Standard Deviation 3.397
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 85 (n=17,8 ) Chge	-2.34 # positive cells	Standard Deviation 3.618
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 8(n=18,10 ) Chge	0.01 # positive cells	Standard Deviation 0.047
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 8(n=11,10 )	6.71 # positive cells	Standard Deviation 4.309
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 29(n=4,0 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 29(n=4,0 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 85(n=17,8)	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 85(n=16,8 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 140(n=17,7 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 140(n=16,7 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 8(n=11,8 ) Chge	-1.75 # positive cells	Standard Deviation 6.143
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Baseline(n=19,8 )	0.02 # positive cells	Standard Deviation 0.071
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 8(n=11,10 )	0.05 # positive cells	Standard Deviation 0.129
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 8(n=11,8 ) Chge	0.03 # positive cells	Standard Deviation 0.159
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 140 (n=18,10 ) Chge	-1.35 # positive cells	Standard Deviation 5.078
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 29(n=5,0 )	8.09 # positive cells	Standard Deviation 11.851
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 29(n=5,0 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 140(n=6,4 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 85 (n=18,8)	0.03 # positive cells	Standard Deviation 0.103
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 140 (n=6,4 ) Chge	-1.20 # positive cells	Standard Deviation 7.929
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 8 (n=11,10)	7.19 # positive cells	Standard Deviation 3.618
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 8 (n=11,8) Chg	0.71 # positive cells	Standard Deviation 2.809
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Baseline(n=19,10 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 8(n=18,10 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 29(n=4,0 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 85(n=17,8) Chg	0.04 # positive cells	Standard Deviation 0.1
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 85(n=17,8 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 85(n=16,8 ) Chge	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 140 (n=17,7 )	0.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Baseline (n=19,8)	0.01 # positive cells	Standard Deviation 0.046
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional day 8 (n=11,10)	0.33 # positive cells	Standard Deviation 1.085
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 8 (n=18,10) Chg	1.14 # positive cells	Standard Deviation 2.989
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 29 (n=4,0)	8.22 # positive cells	Standard Deviation 4.981
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 29(n=5,0)	10.20 # positive cells	Standard Deviation 4.658
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 85(n=10,6) Chg	0.39 # positive cells	Standard Deviation 4.141
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 140(n=7,5)	6.59 # positive cells	Standard Deviation 6.335
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 140(n=7,4) Chg	2.68 # positive cells	Standard Deviation 6.641
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 85(n=10,7)	0.68 # positive cells	Standard Deviation 0.691
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Baseline (n=19,8)	0.42 # positive cells	Standard Deviation 0.459
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 8(n=11,10)	0.55 # positive cells	Standard Deviation 0.561
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 8(n=11,10) Change	0.14 # positive cells	Standard Deviation 0.604
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 29(n=5,0)	0.28 # positive cells	Standard Deviation 0.438
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 29(n=5,0) Change	-0.33 # positive cells	Standard Deviation 0.574
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 85(n=10,7)	0.46 # positive cells	Standard Deviation 0.558
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 85(n=10,6) Change	0.07 # positive cells	Standard Deviation 0.672
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 140(n=7,5)	0.84 # positive cells	Standard Deviation 0.983
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 140(n=7,4) Change	0.27 # positive cells	Standard Deviation 0.843
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Baseline(n=19,10)	9.97 # positive cells	Standard Deviation 4.924
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 8(n=19,10)	10.81 # positive cells	Standard Deviation 5.359
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 8(n=18,10) Change	0.72 # positive cells	Standard Deviation 6.503
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional Baseline (n= 19,10)	1.06 # positive cells	Standard Deviation 1.077
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional Day 8 (n=19,10)	1.41 # positive cells	Standard Deviation 1.313
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 8(n=18,10) Chge	0.39 # positive cells	Standard Deviation 1.351
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 29(n=4,0)	1.00 # positive cells	Standard Deviation 0
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 29(n=4,0) Chg	0.70 # positive cells	Standard Deviation 0.383
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 85(n=18,8)	1.19 # positive cells	Standard Deviation 0.806
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 85(n=17,8) Chge	0.04 # positive cells	Standard Deviation 1.216
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 140(n=17,7)	1.25 # positive cells	Standard Deviation 1.63
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 140(n=17,7) Chge	0.04 # positive cells	Standard Deviation 1.216
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional baseline (n=19,8)	1.17 # positive cells	Standard Deviation 1.363
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D8 (n=11,10)	1.63 # positive cells	Standard Deviation 1.425
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D8 (n=11,8) Change	0.39 # positive cells	Standard Deviation 1.153
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D29 (n=5,0)	1.56 # positive cells	Standard Deviation 1.609
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D29 (n=5,0) Change	0.88 # positive cells	Standard Deviation 1.677
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D85 (n=10,7)	1.18 # positive cells	Standard Deviation 0.577
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D85 (n=10,6) Change	-0.06 # positive cells	Standard Deviation 1.234
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D85 (n=18,8)	17.05 # positive cells	Standard Deviation 5.656
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D85 (n=17,8) Change	-1.52 # positive cells	Standard Deviation 7.562
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D140 (n=17,7)	22.85 # positive cells	Standard Deviation 11.189
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D140 (n=16,7) Change	3.51 # positive cells	Standard Deviation 11.162
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional baseline(n=19,8)	27.14 # positive cells	Standard Deviation 12.552
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D8(n=11,10)	28.85 # positive cells	Standard Deviation 22.24
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D29 (n=5,0) Change	-0.28 # positive cells	Standard Deviation 5.403
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D85 (n=10,7)	24.82 # positive cells	Standard Deviation 13.724
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D85 (n=10,6) Change	-0.09 # positive cells	Standard Deviation 15
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D140 (n=6,5)	37.33 # positive cells	Standard Deviation 21.229
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D140 (n=6,4) Change	11.30 # positive cells	Standard Deviation 23.485
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Baseline (n=19,10)	0.37 # positive cells	Standard Deviation 0.593
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 140 (n=17,7)	0.36 # positive cells	Standard Deviation 0.47
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 29(n=4,0)	6.87 # positive cells	Standard Deviation 1.427
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 29(n=4,0) Change	-1.78 # positive cells	Standard Deviation 3.096
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 85(n=18,8)	12.71 # positive cells	Standard Deviation 9.845
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 85(n=18,8) Change	2.61 # positive cells	Standard Deviation 8.287
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 140(n=17,7)	11.80 # positive cells	Standard Deviation 6.96
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 140(n=16,7) Change	1.03 # positive cells	Standard Deviation 5.717
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Baseline(n=19,8)	12.75 # positive cells	Standard Deviation 6.934
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 8 (n=11,10)	14.93 # positive cells	Standard Deviation 8.543
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 140 (n=7,5)	12.42 # positive cells	Standard Deviation 7.6
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 140(n=7,4) Change	0.93 # positive cells	Standard Deviation 10.179
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 140 (n=16,7) Chge	0.023 # positive cells	Standard Deviation 3.866
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional baseline(n=19,8)	7.64 # positive cells	Standard Deviation 3.71
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 8(n=11,10)	11.25 # positive cells	Standard Deviation 5.742
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 85(n=10,6) Change	-0.20 # positive cells	Standard Deviation 0.847
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 140(n=6,5)	0.03 # positive cells	Standard Deviation 0.082
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Baseline (n=19,10)	0.99 # positive cells	Standard Deviation 1.4
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 8 (n=19,10)	1.20 # positive cells	Standard Deviation 1.428
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 8 (n=18,10) Change	0.33 # positive cells	Standard Deviation 1.287
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 29 (n=4,0)	1.43 # positive cells	Standard Deviation 1.144
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 29 (n=4,0) change	-0.13 # positive cells	Standard Deviation 0.922
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 85(n=18,8)	0.69 # positive cells	Standard Deviation 1.528
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 29(n=5,0)	14.06 # positive cells	Standard Deviation 4.272
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 29(n=5,0) Change	3.74 # positive cells	Standard Deviation 4.844
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 85(n=10,6) Change	2.10 # positive cells	Standard Deviation 5.703
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 140(n=6,5)	9.88 # positive cells	Standard Deviation 4.399
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 140(n=6,4) Change	2.41 # positive cells	Standard Deviation 3.792
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Baseline (n=19,10)	10.59 # positive cells	Standard Deviation 6.616
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 8 (n=19,10)	12.00 # positive cells	Standard Deviation 6.37
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 8 (n=18,10) Change	1.49 # positive cells	Standard Deviation 5.924
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 29 (n=4,0)	10.08 # positive cells	Standard Deviation 2.062
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 29 (n=4,0) Change	-0.47 # positive cells	Standard Deviation 2.968
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 85 (n=18,8)	10.93 # positive cells	Standard Deviation 6.046
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 29(n=5,0) Change	3.20 # positive cells	Standard Deviation 4.25
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 85(n=10,7)	17.20 # positive cells	Standard Deviation 6.815
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 85(n=10,6) Change	3.41 # positive cells	Standard Deviation 7.859
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 140(n=6,5)	12.81 # positive cells	Standard Deviation 10.305
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 140(n=6,4) Change	2.58 # positive cells	Standard Deviation 11.073
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 8(n=11,8) Change	-0.46 # positive cells	Standard Deviation 1.193
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 29(n=5,0)	1.52 # positive cells	Standard Deviation 1.927
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 8(n=11,10)	0.43 # positive cells	Standard Deviation 0.568
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 29(n=5,0)	0.20 # positive cells	Standard Deviation 0.346
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 29(n=5,0) Change	0.08 # positive cells	Standard Deviation 0.363
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=4,0) Change	1.80 # positive cells	Standard Deviation 1.849
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85 (n=18,8) Change	5.51 # positive cells	Standard Deviation 3.725
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85 (n=17,8) Change	-0.46 # positive cells	Standard Deviation 2.757
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=17,7) Change	4.30 # positive cells	Standard Deviation 2.357
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=16,7) Change	-1.74 # positive cells	Standard Deviation 2.726
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis lesional Baseline(n=19,8)	5.67 # positive cells	Standard Deviation 2.983
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 8 (n=18,10) Chge	0.99 # positive cells	Standard Deviation 5.511
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 29 (n=4,0)	12.00 # positive cells	Standard Deviation 4.578
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 29 (n=4,0) Chge	1.05 # positive cells	Standard Deviation 2.996
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 85 (n=18,8)	8.75 # positive cells	Standard Deviation 4.492
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 85 (n=17,8) Chge	-1.62 # positive cells	Standard Deviation 5.338
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 140 (n=17,7)	9.89 # positive cells	Standard Deviation 3.427
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Baseline(n=19,8 )	8.29 # positive cells	Standard Deviation 5.189
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D8(n=11,8) Change	3.56 # positive cells	Standard Deviation 16.705
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D29 (n=5,0)	27.04 # positive cells	Standard Deviation 11.509
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 140 (n=16,7) Change	-0.08 # positive cells	Standard Deviation 0.554
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Baseline(n=19,10)	0.20 # positive cells	Standard Deviation 0.306
IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 85(n=17,8) Change	0.00 # positive cells	Standard Deviation 0.473
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Baseline (n=19,10 )	6.80 # positive cells	Standard Deviation 8.61
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 140 (n=18,10 ) Chge	-4.86 # positive cells	Standard Deviation 7.348
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 140(n=17,7)	0.58 # positive cells	Standard Deviation 0.942
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 85(n=10,6) Change	-0.78 # positive cells	Standard Deviation 1.3489
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D8(n=11,8) Change	0.99 # positive cells	Standard Deviation 8.677
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 140(n=17,7) Chge	-0.75 # positive cells	Standard Deviation 0.939
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 140(n=6,5)	19.80 # positive cells	Standard Deviation 12.617
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 140(n=6,4) Change	-0.15 # positive cells	Standard Deviation 11.3
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional baseline (n=19,8)	3.79 # positive cells	Standard Deviation 8.028
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 8(n=11,10)	0.08 # positive cells	Standard Deviation 0.14
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D8 (n=11,10)	1.19 # positive cells	Standard Deviation 1.329
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 8(n=11,8) Change	-0.11 # positive cells	Standard Deviation 0.236
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Baseline (n=19,10)	1.07 # positive cells	Standard Deviation 1.018
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 8(n=11,8) Change	1.42 # positive cells	Standard Deviation 5.978
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 8(n=19,10 )	0.02 # positive cells	Standard Deviation 0.063
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D8 (n=11,8) Change	-2.74 # positive cells	Standard Deviation 8.466
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 85(n=10,6) Change	3.03 # positive cells	Standard Deviation 2.659
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 8 (n=18,10) Chge	-1.31 # positive cells	Standard Deviation 2.493
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 140(n=6,5)	8.87 # positive cells	Standard Deviation 4.017
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D29 (n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 140(n=6,4) Change	2.88 # positive cells	Standard Deviation 4.907
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 8 (n=19,10)	1.46 # positive cells	Standard Deviation 1.639
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 29 (n=4,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D29 (n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 85(n=10,7)	19.80 # positive cells	Standard Deviation 12.617
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D85 (n=10,7)	0.46 # positive cells	Standard Deviation 0.378
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 8 (n=18,10) Change	0.39 # positive cells	Standard Deviation 1.826
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 8(n=18,10 ) Chge	0.02 # positive cells	Standard Deviation 0.063
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85 (n=18,8) Change	7.62 # positive cells	Standard Deviation 4.288
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 29(n=4,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D85 (n=18,8)	23.73 # positive cells	Standard Deviation 19.031
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 29(n=4,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D85 (n=17,8) Change	-1.23 # positive cells	Standard Deviation 15.514
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 85(n=16,8 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 85(n=10,6) Change	0.98 # positive cells	Standard Deviation 10.706
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 140(n=17,7 )	0.03 # positive cells	Standard Deviation 0.076
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D140 (n=17,7)	15.58 # positive cells	Standard Deviation 9.691
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 8(n=11,10 )	4.80 # positive cells	Standard Deviation 4.512
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 29 (n=4,0) change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 140(n=16,7 ) Chge	0.03 # positive cells	Standard Deviation 0.076
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D140 (n=16,7) Change	-11.51 # positive cells	Standard Deviation 15.849
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Baseline(n=19,8 )	0.03 # positive cells	Standard Deviation 0.071
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 85 (n=17,8 ) Chge	-2.16 # positive cells	Standard Deviation 6.705
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 85 (n=18,8)	9.17 # positive cells	Standard Deviation 2.55
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 8(n=11,10 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional baseline(n=19,8)	22.46 # positive cells	Standard Deviation 9.7
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 8(n=11,8 ) Chge	-0.03 # positive cells	Standard Deviation 0.071
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 140 (n=18,10 )	3.12 # positive cells	Standard Deviation 3.12
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85 (n=17,8) Change	0.35 # positive cells	Standard Deviation 3.067
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 8(n=11,8 ) Chge	0.18 # positive cells	Standard Deviation 3.394
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D8(n=11,10)	22.12 # positive cells	Standard Deviation 8.669
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D29 (n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 29(n=5,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 140(n=6,5)	0.84 # positive cells	Standard Deviation 0.518
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 140(n=6,4 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D29 (n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 140 (n=6,4 ) Chge	4.50 # positive cells	Standard Deviation 5.073
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D85 (n=10,7)	22.59 # positive cells	Standard Deviation 16.719
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 8 (n=11,10)	6.99 # positive cells	Standard Deviation 3.451
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 8(n=11,10)	0.90 # positive cells	Standard Deviation 0.92
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 85 (n=18,8)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D85 (n=10,6) Change	4.07 # positive cells	Standard Deviation 22.288
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Baseline(n=19,10 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 29 (n=4,0) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional day 8(n=19,10 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 85(n=10,7)	8.77 # positive cells	Standard Deviation 2.606
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 8(n=18,10 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D140 (n=6,5)	22.59 # positive cells	Standard Deviation 16.719
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 29(n=4,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 29(n=4,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day140(n=16,7) Chg	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis lesional D140 (n=6,4) Change	12.43 # positive cells	Standard Deviation 9.21
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 85(n=17,8 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 85(n=10,6) Change	-0.97 # positive cells	Standard Deviation 3.885
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 85(n=16,8 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 85 (n=17,8) Change	-0.46 # positive cells	Standard Deviation 1.249
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 8(n=11,8) Change	-0.04 # positive cells	Standard Deviation 0.68
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Baseline (n=19,8)	0.08 # positive cells	Standard Deviation 0.149
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 140 (n=17,7)	0.75 # positive cells	Standard Deviation 1.245
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 8 (n=19,10)	8.37 # positive cells	Standard Deviation 2.305
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 140(n=6,5)	8.66 # positive cells	Standard Deviation 2.136
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 8 (n=18,10) Chg	1.17 # positive cells	Standard Deviation 3.03
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 29(n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 8 (n=11,8) Chg	0.88 # positive cells	Standard Deviation 2.998
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=17,7) Change	5.09 # positive cells	Standard Deviation 3.523
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 85(n=10,7)	6.93 # positive cells	Standard Deviation 3.135
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 85(n=10,7)	0.47 # positive cells	Standard Deviation 0.432
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 85(n=10,6) Chg	1.67 # positive cells	Standard Deviation 2.047
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 29(n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 140(n=7,5)	6.79 # positive cells	Standard Deviation 1.635
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 140(n=6,4) Change	-0.98 # positive cells	Standard Deviation 3.444
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 140(n=7,4) Chg	1.97 # positive cells	Standard Deviation 2.049
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 85(n=18,8)	11.46 # positive cells	Standard Deviation 7.9
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 140 (n=16,7) Change	-0.09 # positive cells	Standard Deviation 2.092
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 140 (n=17,7)	8.01 # positive cells	Standard Deviation 2.744
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Baseline (n=19,8)	0.49 # positive cells	Standard Deviation 0.892
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 85(n=18,8) Change	-2.09 # positive cells	Standard Deviation 5.865
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 8(n=11,10)	0.84 # positive cells	Standard Deviation 0.913
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Baseline (n=19,10)	10.11 # positive cells	Standard Deviation 2.91
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 8(n=11,10) Change	0.11 # positive cells	Standard Deviation 1.058
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 140(n=17,7)	7.22 # positive cells	Standard Deviation 5.823
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=16,7) Change	-2.65 # positive cells	Standard Deviation 1.686
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 140(n=16,7) Change	-6.15 # positive cells	Standard Deviation 10.618
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 85(n=10,7)	0.47 # positive cells	Standard Deviation 0.499
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 8 (n=19,10)	9.20 # positive cells	Standard Deviation 3.319
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 85(n=10,6) Change	-0.09 # positive cells	Standard Deviation 0.873
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Baseline(n=19,8)	11.94 # positive cells	Standard Deviation 6.245
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 140(n=7,5)	0.94 # positive cells	Standard Deviation 0.969
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis lesional Day 140(n=7,4) Change	0.98 # positive cells	Standard Deviation 0.642
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 8 (n=11,10)	12.56 # positive cells	Standard Deviation 8.894
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Baseline(n=19,10)	12.46 # positive cells	Standard Deviation 7.954
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 8 (n=18,10) Change	-0.91 # positive cells	Standard Deviation 3.078
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 8(n=19,10)	8.66 # positive cells	Standard Deviation 4.495
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 140 (n=7,5)	14.58 # positive cells	Standard Deviation 19.403
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis non lesional Day 8(n=18,10) Change	-3.80 # positive cells	Standard Deviation 5.984
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 29 (n=4,0) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional Baseline (n= 19,10)	1.25 # positive cells	Standard Deviation 0.584
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional Day 8 (n=19,10)	0.95 # positive cells	Standard Deviation 0.92
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 140 (n=16,7) Chge	-2.43 # positive cells	Standard Deviation 2.234
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 8(n=18,10) Chge	-0.30 # positive cells	Standard Deviation 1.255
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 29(n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional baseline(n=19,8)	10.18 # positive cells	Standard Deviation 3.804
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 29(n=4,0) Chg	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 29 (n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 85(n=18,8)	0.53 # positive cells	Standard Deviation 0.544
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 8(n=11,10)	10.84 # positive cells	Standard Deviation 3.865
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis Non lesional D 85(n=17,8) Chge	-0.84 # positive cells	Standard Deviation 0.524
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 85 (n=17,8) Chge	-1.02 # positive cells	Standard Deviation 4.166
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis lesional Baseline(n=19,8)	4.63 # positive cells	Standard Deviation 2.448
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8(n=11,10)	6.12 # positive cells	Standard Deviation 3.847
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8(n=11,8) Change	0.88 # positive cells	Standard Deviation 2.679
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85(n=10,7)	6.70 # positive cells	Standard Deviation 6.69
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 85(n=10,6) Change	1.48 # positive cells	Standard Deviation 6.628
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=6,5)	6.37 # positive cells	Standard Deviation 10.549
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Baseline (n=19,10)	10.99 # positive cells	Standard Deviation 4.498
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis non lesional Day 8 (n=19,10)	9.68 # positive cells	Standard Deviation 3.057
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 140(n=17,8) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 29(n=5,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 85 (n=18,8 )	5.28 # positive cells	Standard Deviation 4.906
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Day 85(n=17,8)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 140(n=6,4)	3.57 # positive cells	Standard Deviation 10.671
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 140 (n=16,7) Change	-3.79 # positive cells	Standard Deviation 2.284
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Baseline(n=19,8)	7.31 # positive cells	Standard Deviation 2.468
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 85(n=10,7)	9.51 # positive cells	Standard Deviation 2.891
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Baseline (n=19,10)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 8 (n=19,10)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 8 (n=18,10) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 85 (n=18,8)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 85 (n=17,8)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 29(n=5,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis non lesional Day 140(n=18,8)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Baseline (n=19,8)	0.03 # positive cells	Standard Deviation 0.071
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 8 (n=11,10)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 8 (n=11,8) Chge	-0.03 # positive cells	Standard Deviation 0.071
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 85 (n=10,6)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 85 (n=10,5) Chge	-.04 # positive cells	Standard Deviation 0.089
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 140(n=6,5 )	1.00 # positive cells	Standard Deviation 2.236
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Epidermis lesional Day 140(n=6,4 ) Chge	1.25 # positive cells	Standard Deviation 2.5
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 8 (n=19,10 )	4.47 # positive cells	Standard Deviation 4.529
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 8 (n=18,10 ) Chge	-2.33 # positive cells	Standard Deviation 4.75
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis non lesional Day 29 (n=4,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Baseline(n=19,8 )	4.79 # positive cells	Standard Deviation 5.931
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 29(n=5,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 85(n=10,6 )	0.03 # positive cells	Standard Deviation 0.082
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 29 (n=4,0) Chg	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 29(n=5,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 85(n=10,5 ) Chge	0.04 # positive cells	Standard Deviation 0.089
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis lesional Day 140(n=6,5 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 85 (n=18,8)	8.33 # positive cells	Standard Deviation 3.547
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Baseline (n=19,10)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 85 (n=17,8) Chg	1.35 # positive cells	Standard Deviation 3.839
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 8 (n=19,10)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 8(n=18,10) Chg	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 29(n=5,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 85(n=10,6 )	10.30 # positive cells	Standard Deviation 15.647
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 85 (n=10,5 ) Chge	6.36 # positive cells	Standard Deviation 9.563
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 140 (n=17,7)	6.95 # positive cells	Standard Deviation 1.812
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Day 140 (n=16,7) Chg	-0.62 # positive cells	Standard Deviation 3.002
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Baseline (n=19,8)	6.41 # positive cells	Standard Deviation 2.658
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Giemsa Dermis lesional Day 140(n=6,5 )	9.44 # positive cells	Standard Deviation 10.468
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 29 (n=4,0) Chg	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 85(n=17,8) Chg	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis non lesional Day 140 (n=17,7)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional day 8 (n=11,10)	0.10 # positive cells	Standard Deviation 0.316
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 140 (n=17,7 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 8 (n=11,8) Chg	0.05 # positive cells	Standard Deviation 0.334
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis non lesional Day 140 (n=16,7 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 29 (n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Baseline(n=19,8 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 8(n=11,10 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 8(n=11,8 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 29(n=5,0 )	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 29(n=5,0 ) Chge	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 29 (n=5,0) Chg	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 85(n=10,7)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 85(n=10,6 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 85(n=10,6) Chg	-0.10 # positive cells	Standard Deviation 0.167
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 85(n=10,5 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 140 (n=7,5)	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Epidermis lesional Day 140 (n=7,4) Chg	-0.10 # positive cells	Standard Deviation 0.2
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 140(n=6,5 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Epidermis lesional Day 140(n=6,4 ) Chge	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	H&E Dermis non lesional Baseline(n=19,10 )	0.00 # positive cells	Standard Deviation 0
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis non lesional Baseline (n=19,10)	7.20 # positive cells	Standard Deviation 3.045
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	Tryptase Dermis lesional Day 29(n=5,0) Chg	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D85 (n=10,6) Change	-4.06 # positive cells	Standard Deviation 9.384
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D140 (n=6,5)	0.18 # positive cells	Standard Deviation 0.171
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Epidermis lesional D140 (n=6,5) Change	-6.37 # positive cells	Standard Deviation 11.503
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional baseline (n=19,10)	22.97 # positive cells	Standard Deviation 12.248
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D8 (n=19,10)	20.22 # positive cells	Standard Deviation 10.861
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D8 (n=19,10) Change	-2.75 # positive cells	Standard Deviation 6.149
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD11c Dermis non lesional D29 (n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Baseline (n=19,10)	0.68 # positive cells	Standard Deviation 1.151
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 8 (n=19,10)	0.34 # positive cells	Standard Deviation 0.422
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 8 (n=18,10) Change	-0.34 # positive cells	Standard Deviation 1.091
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 29 (n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 29 (n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Epidermis non lesional Day 85 (n=18,8)	0.30 # positive cells	Standard Deviation 0.283
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 8 (n=11,10) Change	1.58 # positive cells	Standard Deviation 7.177
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 29 (n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional day 29 (n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 85 (n=10,7)	14.44 # positive cells	Standard Deviation 13.122
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 85 (n=10,6) Change	2.24 # positive cells	Standard Deviation 13.351
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD3 Dermis lesional Day 140(n=7,4) Change	6.33 # positive cells	Standard Deviation 20.884
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Epidermis lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 85(n=18,8)	0.44 # positive cells	Standard Deviation 0.36
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 140(n=6,4) Change	-0.73 # positive cells	Standard Deviation 1.473
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epdiermis non lesional Day 85(n=18,8) Change	-0.49 # positive cells	Standard Deviation 0.797
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 140(n=17,7)	0.76 # positive cells	Standard Deviation 1.355
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis non lesional Day 140(n=16,7) Change	-0.04 # positive cells	Standard Deviation 1.802
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Baseline(n=19,8)	0.91 # positive cells	Standard Deviation 1.204
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Baseline(n=19,10)	19.39 # positive cells	Standard Deviation 13.966
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 8(n=19,10)	16.04 # positive cells	Standard Deviation 10.59
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 85 (n=18,8)	11.18 # positive cells	Standard Deviation 4.568
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 85 (n=17,8) Change	0.52 # positive cells	Standard Deviation 3.239
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis non lesional Day 140(n=17,7)	7.22 # positive cells	Standard Deviation 2.1
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 8(n=11,10)	8.08 # positive cells	Standard Deviation 2.743
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 8(n=11,8) Change	1.26 # positive cells	Standard Deviation 2.89
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD117 Dermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 8(n=18,10) Change	-3.35 # positive cells	Standard Deviation 10.063
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 29(n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 29(n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 85(n=18,8) Change	19.21 # positive cells	Standard Deviation 10.316
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 85(n=17,8) Change	-2.32 # positive cells	Standard Deviation 9.451
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 140(n=17,7)	16.90 # positive cells	Standard Deviation 10.151
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis non lesional Day 140(n=16,7) Change	-2.01 # positive cells	Standard Deviation 13.6
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional baseline(n=19,8)	18.98 # positive cells	Standard Deviation 9.361
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 8(n=11,10)	17.74 # positive cells	Standard Deviation 9.23
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 8(n=11,8) Change	0.10 # positive cells	Standard Deviation 10.085
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Dermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epidermis lesional Day 29(n=5,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD4 Epdiermis lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Baseline(n=19,10)	0.24 # positive cells	Standard Deviation 0.42
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 8(n=19,10)	0.20 # positive cells	Standard Deviation 0.34
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 8(n=18,10) Change	-0.04 # positive cells	Standard Deviation 0.532
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 29(n=4,0)	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 29(n=4,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 85(n=18,8)	0.15 # positive cells	Standard Deviation 0.207
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 85(n=17,8) Change	-0.13 # positive cells	Standard Deviation 0.354
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 140(n=17,7)	0.28 # positive cells	Standard Deviation 0.351
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis non lesional Day 140(n=16,7) Change	-0.01 # positive cells	Standard Deviation 0.566
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Baseline(n=19,8)	0.14 # positive cells	Standard Deviation 0.207
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 29(n=5,0) Change	NA # positive cells	—
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 85(n=10,7)	0.03 # positive cells	Standard Deviation 0.076
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 85(n=10,6) Change	-0.15 # positive cells	Standard Deviation 0.235
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 140(n=6,5)	0.33 # positive cells	Standard Deviation 0.239
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Epidermis lesional Day 140(n=6,4) Change	0.18 # positive cells	Standard Deviation 0.304
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Baseline(n=19,10)	6.59 # positive cells	Standard Deviation 3.826
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8(n=19,10)	5.50 # positive cells	Standard Deviation 3.779
Placebo IGE025	Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit	CD8 Dermis non lesional Day 8 (n=18,10) Change	-1.09 # positive cells	Standard Deviation 1.374

Secondary

Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.

Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry that provides a method for sorting a heterogeneous mixture of biological cells into two or more containers, one cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. (FACS) provides fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest. A wide range of fluorophores can be used as labels in flow cytometry. Fluorophores are typically attached to an antibody that recognizes a target feature on or in the cell; they may also be attached to a chemical entity with affinity for the cell membrane or another cellular structure. Each fluorophore has a characteristic peak excitation and emission wavelength.

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells bound IgE D1 (n=8,8)	4.53 % out of leukocytes	Standard Deviation 5.001
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Basophils D1 (n=19,10) Units	0.23 % out of leukocytes	Standard Deviation 0.132
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells bound IgE D85(n=5,7)	7.32 % out of leukocytes	Standard Deviation 7.579
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells Chge (n=7,7)	0.31 % out of leukocytes	Standard Deviation 1.377
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells bound IgE chge (n=5,7	1.46 % out of leukocytes	Standard Deviation 3.545
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Basophils D85 (n=7,5) Units	0.47 % out of leukocytes	Standard Deviation 0.215
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells D1 (n=10,9)	3.57 % out of leukocytes	Standard Deviation 2.298
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells D85 (n=7,7)	3.84 % out of leukocytes	Standard Deviation 1.595
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Dendritic cells D85 (n=8,5)	0.37 % out of leukocytes	Standard Deviation 0.231
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Basophils chge (n=7,5) Units	0.22 % out of leukocytes	Standard Deviation 0.268
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Dendritic cells Chge (n=7,5)	0.02 % out of leukocytes	Standard Deviation 0.272
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Dendritic cells D1 (n=10,7)	0.37 % out of leukocytes	Standard Deviation 0.196
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Dendritic cells Chge (n=7,5)	-0.02 % out of leukocytes	Standard Deviation 0.182
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells D85 (n=7,7)	3.25 % out of leukocytes	Standard Deviation 2.007
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells Chge (n=7,7)	0.73 % out of leukocytes	Standard Deviation 0.805
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Basophils D1 (n=19,10) Units	0.36 % out of leukocytes	Standard Deviation 0.482
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Basophils D85 (n=7,5) Units	0.40 % out of leukocytes	Standard Deviation 0.451
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Basophils chge (n=7,5) Units	-0.06 % out of leukocytes	Standard Deviation 0.176
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells bound IgE D1 (n=8,8)	15.19 % out of leukocytes	Standard Deviation 22.609
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells bound IgE D85(n=5,7)	25.66 % out of leukocytes	Standard Deviation 26.485
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells bound IgE chge (n=5,7	12.53 % out of leukocytes	Standard Deviation 21.725
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	CD19+ B cells D1 (n=10,9)	2.5 % out of leukocytes	Standard Deviation 1.247
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Dendritic cells D85 (n=8,5)	0.27 % out of leukocytes	Standard Deviation 0.21
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.	Dendritic cells D1 (n=10,7)	0.24 % out of leukocytes	Standard Deviation 0.14

Secondary

Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.• FACS parameters: FceRI expression on basophils and IgE bound, FceR2 expression on B cells and IgE bound, and FceRI expression on dendritic cells

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	CD19+ B cells with FcεR2 exp D1 (n=10,9)	59040 Flourescence units	Standard Deviation 42446
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	CD19+ B cells with FcεR2 exp D85 (n=7,7)	59429 Flourescence units	Standard Deviation 55980
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with FcεR1 exp D1 (n=11,8)	292391 Flourescence units	Standard Deviation 135848
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with FcεR1 exp D85 (n=7,5)	79457 Flourescence units	Standard Deviation 29333
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	CD19+ B cells with FcεR2 exp chge (n=7,7)	12814 Flourescence units	Standard Deviation 32631
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with FcεR1 expression Chge (n=6,5)	-243700 Flourescence units	Standard Deviation 118883
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with bound IgE D 1 (n=11,7)	149656 Flourescence units	Standard Deviation 112936
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with bound IgE D85 (n=7,5)	9554 Flourescence units	Standard Deviation 6214
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with bound IgE Chge (n=6,5)	-178487 Flourescence units	Standard Deviation 103456
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Dendritic cells with FcεR1 expr D1 (n=10,7)	40880 Flourescence units	Standard Deviation 17191
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Dendritic cells with FcεR1 expr D85 (n=6,5)	38283 Flourescence units	Standard Deviation 5768
IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Dendritic cells with FcεR1 expr Chge (n=5,5)	-10100 Flourescence units	Standard Deviation 16887
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with bound IgE D 1 (n=11,7)	236071 Flourescence units	Standard Deviation 89043
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	CD19+ B cells with FcεR2 exp D1 (n=10,9)	59700 Flourescence units	Standard Deviation 27171
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Dendritic cells with FcεR1 expr Chge (n=5,5)	-516 Flourescence units	Standard Deviation 5925
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with bound IgE D85 (n=7,5)	212620 Flourescence units	Standard Deviation 109645
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with FcεR1 exp D1 (n=11,8)	312038 Flourescence units	Standard Deviation 147037
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Dendritic cells with FcεR1 expr D1 (n=10,7)	43029 Flourescence units	Standard Deviation 12363
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with FcεR1 exp D85 (n=7,5)	291000 Flourescence units	Standard Deviation 108028
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	CD19+ B cells with FcεR2 exp D85 (n=7,7)	49243 Flourescence units	Standard Deviation 33460
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with bound IgE Chge (n=6,5)	-12680 Flourescence units	Standard Deviation 59998
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	CD19+ B cells with FcεR2 exp chge (n=7,7)	3986 Flourescence units	Standard Deviation 16779
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Basophils with FcεR1 expression Chge (n=6,5)	-38260 Flourescence units	Standard Deviation 60085
Placebo IGE025	Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.	Dendritic cells with FcεR1 expr D85 (n=6,5)	36962 Flourescence units	Standard Deviation 18562

Secondary

Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit

Time frame: Baseline through Day 85

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Baseline (n=19,10)	5.0526 ug/mL	Standard Deviation 2.06757
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 29 (n=20,9)	2.5869 ug/mL	Standard Deviation 2.31661
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 2 (n=20,10)	4.1500 ug/mL	Standard Deviation 1.6111
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 2 (n=20,9)	0.0836 ug/mL	Standard Deviation 0.0663
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 8 (n=20,10)	4.5000 ug/mL	Standard Deviation 2.01311
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 2 (n=20, 10)	2.8190 ug/mL	Standard Deviation 2.94786
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 15 (n=19,8)	4.5789 ug/mL	Standard Deviation 1.6437
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 8 (n=19,8)	0.0910 ug/mL	Standard Deviation 0.07704
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 29 (n=20,9)	5.1500 ug/mL	Standard Deviation 2.20705
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 85 (n=17,8)	2.5178 ug/mL	Standard Deviation 1.93931
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 85 (n=17,8)	5.8235 ug/mL	Standard Deviation 1.50977
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 15 (n=19,7)	0.0883 ug/mL	Standard Deviation 0.06303
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 140 (n=18,10)	4.8333 ug/mL	Standard Deviation 2.64019
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 15 (n=19,8)	2.2711 ug/mL	Standard Deviation 1.98781
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Baseline (n=19,10)	0.4858 ug/mL	Standard Deviation 0.09955
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 29 (n=20,9)	0.0881 ug/mL	Standard Deviation 0.07624
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 2 (n=20,10)	0.4468 ug/mL	Standard Deviation 0.07872
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 140 (n=18,10)	2.022 ug/mL	Standard Deviation 2.44218
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 8 (n=20,10)	0.4967 ug/mL	Standard Deviation 0.12551
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 85 (n=17,8)	0.0714 ug/mL	Standard Deviation 0.03079
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 15 (n=19,8)	0.4788 ug/mL	Standard Deviation 0.12577
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 8 (n=20,10)	2.5597 ug/mL	Standard Deviation 2.22009
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 29 (n=20,9)	0.4633 ug/mL	Standard Deviation 0.10172
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 140 (n=18,9)	0.0864 ug/mL	Standard Deviation 0.07319
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 85 ( n= 17,8)	0.4314 ug/mL	Standard Deviation 0.10424
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Baseline (n=19,10)	0.1020 ug/mL	Standard Deviation 0.07807
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 140 ( n=15,10)	0.4314 ug/mL	Standard Deviation 0.10921
IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Baseline (n=19,10)	2.9669 ug/mL	Standard Deviation 2.31825
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 140 ( n=15,10)	0.4918 ug/mL	Standard Deviation 0.1525
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Baseline (n=19,10)	3.0394 ug/mL	Standard Deviation 2.38102
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 2 (n=20, 10)	3.3035 ug/mL	Standard Deviation 3.52023
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 8 (n=20,10)	2.2742 ug/mL	Standard Deviation 1.58648
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 15 (n=19,8)	2.0216 ug/mL	Standard Deviation 1.46346
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 29 (n=20,9)	2.2826 ug/mL	Standard Deviation 1.56237
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 85 (n=17,8)	1.8724 ug/mL	Standard Deviation 1.16171
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CCR3 Day 140 (n=18,10)	2.4060 ug/mL	Standard Deviation 1.85351
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Baseline (n=19,10)	0.0638 ug/mL	Standard Deviation 0.07208
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 2 (n=20,9)	0.0621 ug/mL	Standard Deviation 0.06496
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 8 (n=19,8)	0.0772 ug/mL	Standard Deviation 0.0599
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 15 (n=19,7)	0.0546 ug/mL	Standard Deviation 0.0255
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 29 (n=20,9)	0.0601 ug/mL	Standard Deviation 0.04219
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 85 (n=17,8)	0.0430 ug/mL	Standard Deviation 0.0291
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine CXCR3/IP-10 Day 140 (n=18,9)	0.0859 ug/mL	Standard Deviation 0.07489
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Baseline (n=19,10)	5.2000 ug/mL	Standard Deviation 1.13529
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 2 (n=20,10)	5.0000 ug/mL	Standard Deviation 1.76383
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 8 (n=20,10)	5.4000 ug/mL	Standard Deviation 2.01108
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 15 (n=19,8)	4.7500 ug/mL	Standard Deviation 1.83225
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 29 (n=20,9)	4.7778 ug/mL	Standard Deviation 3.38296
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 85 (n=17,8)	5.0000 ug/mL	Standard Deviation 1.30931
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Histamine Day 140 (n=18,10)	5.7000 ug/mL	Standard Deviation 1.76698
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Baseline (n=19,10)	0.5191 ug/mL	Standard Deviation 0.14846
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 2 (n=20,10)	0.4975 ug/mL	Standard Deviation 0.14406
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 8 (n=20,10)	0.4728 ug/mL	Standard Deviation 0.15713
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 15 (n=19,8)	0.4709 ug/mL	Standard Deviation 0.11789
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 29 (n=20,9)	0.4704 ug/mL	Standard Deviation 0.11356
Placebo IGE025	Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit	Chemokine ICAM-1 Day 85 ( n= 17,8)	0.4037 ug/mL	Standard Deviation 0.05599

Secondary

Percentage of Angioedema-free Days Weeks 4 Through 12 by Treatment

Time frame: Day 29 to Day 85

Population: Efficacy analysis set which included all randomized patients who received at least one dose of study drug and had post-randomization efficacy data

Arm	Measure	Value (MEAN)	Dispersion
IGE025	Percentage of Angioedema-free Days Weeks 4 Through 12 by Treatment	90.9 Percentage of days	Standard Deviation 22.83
Placebo IGE025	Percentage of Angioedema-free Days Weeks 4 Through 12 by Treatment	70.5 Percentage of days	Standard Deviation 28.5

Secondary

Serum Levels of Omalizumab

Serum concentrations (ng/mL) of omalizumab by visit after the administration of omalizumab 300 mg every 4 weeks

Time frame: Baseline through Day 85

Population: PK analysis set which included all subjects who received at least one dose of study drug and had evaluable IGE025 concentrations.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Serum Levels of Omalizumab	Day 1	0.0 ng/mL	Standard Deviation 0
IGE025	Serum Levels of Omalizumab	Day 2	13400 ng/mL	Standard Deviation 4690
IGE025	Serum Levels of Omalizumab	Day 8	30100 ng/mL	Standard Deviation 7800
IGE025	Serum Levels of Omalizumab	Day 29	17000 ng/mL	Standard Deviation 5500
IGE025	Serum Levels of Omalizumab	Day 57	25000 ng/mL	Standard Deviation 8640
IGE025	Serum Levels of Omalizumab	Day 85	28800 ng/mL	Standard Deviation 11400

Secondary

Skindex-29 by Treatment

The Skindex-29 is a validated 29-item instrument to measure the effects of skin disease on patients' quality of life.Results are reported as 3 scale scores (functioning, emotions and symptoms) and a composite score (average scale score). The domain scores and the overall score are expressed on a 100-point scale, with higher scores indicating a lower level of quality of life. The cuttoff values for each category are noted below. Symtoms; 39 mild, 42 moderate,52 severe. Emotions; 24 mild, 35 moderate, 39 severe. Functioning: 21 mild, 32 moderate, 37 severe. Overal Score: 25 mild, 32 moderate, 44 severe.

Time frame: Baseline and Day 85

Population: Efficacy analysis set which included all randomized patients who received at least one dose of study drug and had post-randomization efficacy data

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Skindex-29 by Treatment	Baseline (n= 16,9)	17.98 Score	Standard Deviation 7.807
IGE025	Skindex-29 by Treatment	Day 85 (n=16,8)	6.17 Score	Standard Deviation 7.119
Placebo IGE025	Skindex-29 by Treatment	Baseline (n= 16,9)	21.67 Score	Standard Deviation 9.068
Placebo IGE025	Skindex-29 by Treatment	Day 85 (n=16,8)	22.63 Score	Standard Deviation 10.276

Secondary

Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit

Time frame: Baseline through Day 140

Population: All subjects who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data were included in the PD data analysis.

Arm	Measure	Group	Value (MEAN)	Dispersion
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Common Silver Birch Absolute Change (n = 4,3)	-10.2145 IU/mL	Standard Deviation 26.47094
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Alternaria alternara Baseline (n= 0, 1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Artemisia vulgaris (Mugwort) Baseline (n=1,1)	0.2730 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Artemisia vulgaris (Mugwort) Day 140( n=0,1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Cat dander Basseline (n=3,1)	17.9677 IU/mL	Standard Deviation 22.73833
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Cat dander Day 140 (n=2,1)	21.0100 IU/mL	Standard Deviation 26.14881
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Common silver Birch Baseline (n=6,3)	12.3640 IU/mL	Standard Deviation 19.48667
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Common silver Birch Day 140 (n=4,3)	4.4890 IU/mL	Standard Deviation 6.15938
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dog dander Baseline (n=2,1)	26.7720 IU/mL	Standard Deviation 37.09199
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dog dander Day 140 (n=1,1)	50.1000 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides farinae Baseline (n=3,1)	3.3333 IU/mL	Standard Deviation 3.39883
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides farinae Day 140 (n=2,1)	5.3200 IU/mL	Standard Deviation 0.89095
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides pteronyssinus Baseline (n=5,1)	2.1250 IU/mL	Standard Deviation 1.46791
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides pteronyssinus Day 140(n=4,1)	5.2463 IU/mL	Standard Deviation 3.72052
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Grey Alder (t2) Baseline (n=4,3)	15.7650 IU/mL	Standard Deviation 20.03961
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Grey Alder (t2) Day 140(n=3,3)	4.4900 IU/mL	Standard Deviation 5.16654
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	German Cockroach Baseline (n=4,2)	0.8605 IU/mL	Standard Deviation 0.93609
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	German Cockroach Day 140 (n=4,2)	3.0263 IU/mL	Standard Deviation 2.8719
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Hazelnut Baseline (n=3,3)	8.9627 IU/mL	Standard Deviation 14.49722
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Hazelnut Day 140 (n=2,3)	1.4450 IU/mL	Standard Deviation 1.50977
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Olive (black, fresh) Baseline (n=4,1)	0.0890 IU/mL	Standard Deviation 0.178
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Olive (black, fresh) Day 140 (n=3,1)	0.1037 IU/mL	Standard Deviation 0.17956
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Platanus acerifolia Baseline (n=1,1)	0.1210 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Platanus acerifolia Day 140 (n=0,1)	0.0000 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Parietaria judaica Baseline(n=0,1)	0.0000 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Parietaria judaica Day 140 (n=0,1)	0.0000 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin A Baseline (n=20,10)	0.7264 IU/mL	Standard Deviation 3.07821
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin A Day 140 (n=18,10)	1.6161 IU/mL	Standard Deviation 4.39936
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin C Baseline (n=20,10)	0.8976 IU/mL	Standard Deviation 3.02621
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin C Day 140 (n=18,10)	2.1089 IU/mL	Standard Deviation 4.19834
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin TSST Baseline (n=20,10)	0.5390 IU/mL	Standard Deviation 1.02581
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin TSST Day 140 (n=18,10)	0.8402 IU/mL	Standard Deviation 1.05356
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Alternaria alternara Absolute Change (n = 0,1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Artemisia vulgaris Absolute Change (n = 0,1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Cat dander Absolute Change (n = 2,1)	-1.1315 IU/mL	Standard Deviation 4.33951
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Alternaria alternara Day 140 (n= 0,1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dog dander Absolute Change (n = 1,1)	-2.9000 IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides farinae Absolute Change(n=2,1)	3.9350 IU/mL	Standard Deviation 1.46371
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides pteronyssinus Abs Chge (n=4,1)	3.6800 IU/mL	Standard Deviation 3.05938
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Grey Alder Absolute Change(n=3,3)	-12.6300 IU/mL	Standard Deviation 27.47614
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	German Cockroach Absolute Change(n=4,2)	2.1658 IU/mL	Standard Deviation 2.03436
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Hazelnut Absolute Change(n=2,3)	-11.83000 IU/mL	Standard Deviation 18.1585
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Olive (black, fresh) Absolute Change(n=3,1)	-0.0150 IU/mL	Standard Deviation 0.02598
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Platanus acerifolia Absolute Change(n=0,1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Parietaria judaica Absolute Change(n=0,1)	NA IU/mL	—
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin A Abs chge (n=18,10)	0.8090 IU/mL	Standard Deviation 2.63582
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin C Abs chge (n=18,10)	1.1116 IU/mL	Standard Deviation 2.26524
IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin TSST Abs chge(n=18,10)	0.2608 IU/mL	Standard Deviation 0.72963
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Parietaria judaica Absolute Change(n=0,1)	0.5100 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin C Day 140 (n=18,10)	0.1922 IU/mL	Standard Deviation 0.28071
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Hazelnut Absolute Change(n=2,3)	1.6660 IU/mL	Standard Deviation 2.47183
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Platanus acerifolia Day 140 (n=0,1)	4.8300 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Alternaria alternara Baseline (n= 0, 1)	0.1360 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Alternaria alternara Day 140 (n= 0,1)	0.1140 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Common Silver Birch Absolute Change (n = 4,3)	2.4833 IU/mL	Standard Deviation 5.63479
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Artemisia vulgaris (Mugwort) Baseline (n=1,1)	1.4800 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Parietaria judaica Baseline(n=0,1)	1.4900 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Artemisia vulgaris (Mugwort) Day 140( n=0,1)	1.9100 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin C Abs chge (n=18,10)	0.0296 IU/mL	Standard Deviation 0.06545
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Cat dander Basseline (n=3,1)	0.6980 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Parietaria judaica Day 140 (n=0,1)	2.0000 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Cat dander Day 140 (n=2,1)	0.8980 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dog dander Absolute Change (n = 1,1)	0.1570 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Common silver Birch Baseline (n=6,3)	12.3767 IU/mL	Standard Deviation 11.22609
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin A Baseline (n=20,10)	0.0741 IU/mL	Standard Deviation 0.1358
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Common silver Birch Day 140 (n=4,3)	14.8600 IU/mL	Standard Deviation 16.58164
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Olive (black, fresh) Absolute Change(n=3,1)	0.0000 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dog dander Baseline (n=2,1)	0.5120 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin A Day 140 (n=18,10)	0.1077 IU/mL	Standard Deviation 0.15294
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dog dander Day 140 (n=1,1)	0.6690 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides farinae Absolute Change(n=2,1)	0.0630 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides farinae Baseline (n=3,1)	0.4340 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin C Baseline (n=20,10)	0.1626 IU/mL	Standard Deviation 0.27226
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides farinae Day 140 (n=2,1)	0.4970 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin A Abs chge (n=18,10)	0.0336 IU/mL	Standard Deviation 0.09116
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides pteronyssinus Baseline (n=5,1)	0.4550 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides pteronyssinus Abs Chge (n=4,1)	0.0620 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Dermatophagoides pteronyssinus Day 140(n=4,1)	0.5170 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin TSST Baseline (n=20,10)	0.1537 IU/mL	Standard Deviation 0.23902
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Grey Alder (t2) Baseline (n=4,3)	10.9533 IU/mL	Standard Deviation 10.92027
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Platanus acerifolia Absolute Change(n=0,1)	1.1200 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Grey Alder (t2) Day 140(n=3,3)	13.0533 IU/mL	Standard Deviation 15.24029
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin TSST Day 140 (n=18,10)	0.1468 IU/mL	Standard Deviation 0.22155
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	German Cockroach Baseline (n=4,2)	0.4425 IU/mL	Standard Deviation 0.62579
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Grey Alder Absolute Change(n=3,3)	2.1000 IU/mL	Standard Deviation 4.509
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	German Cockroach Day 140 (n=4,2)	0.4705 IU/mL	Standard Deviation 0.66539
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Alternaria alternara Absolute Change (n = 0,1)	-0.0220 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Hazelnut Baseline (n=3,3)	7.3267 IU/mL	Standard Deviation 8.2816
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Staphylococcal enterotoxin TSST Abs chge(n=18,10)	-0.0069 IU/mL	Standard Deviation 0.15669
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Hazelnut Day 140 (n=2,3)	8.9927 IU/mL	Standard Deviation 10.59244
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Artemisia vulgaris Absolute Change (n = 0,1)	0.4300 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Olive (black, fresh) Baseline (n=4,1)	0.0000 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	German Cockroach Absolute Change(n=4,2)	0.0280 IU/mL	Standard Deviation 0.0396
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Olive (black, fresh) Day 140 (n=3,1)	0.0000 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Cat dander Absolute Change (n = 2,1)	0.2000 IU/mL	—
Placebo IGE025	Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit	Platanus acerifolia Baseline (n=1,1)	3.7100 IU/mL	—

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026

Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin

Observed Values and Absolute Change From Baseline in IgE Positive Skin Cells: Dermis, Lesional and Non Lesional Skin

Change From Baseline in Dermatology Life Quality Index (DLQI) by Treatment

Change From Baseline in Urticaria Activity Score (UAS7)

Chronic Urticaria Quality of Life Questionnaire (Cu-Q2OL) by Treatment

Comparison of Baseline PD Parameters Between Healthy Volunteers and Urticaria Patients by Skin Layer Pharmacodynamic Analysis Set

Correlation of Change From Baseline in IgE on Positive Skin Cells With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status

Correlation of Change From Baseline in IgE Receptor FceRI With Change From Baseline in UAS7 at Week 12 by Treatment, Skin Layer and Lesion Status

Likert Scale-Physician's and Patients In-clinic Global Assessment by Treatment

Mean (SD) Serum Free IgE % Change From Baseline by Visit

Mean (SD) Serum Free IgE Concentration From Baseline by Visit

Mean (SD) Serum Total IgE % Change From Baseline by Visit

Mean (SD) Serum Total IgE Concentration From Baseline by Visit

Observed Values and Absolute Change From Baseline in Skin Cell Subsets (CD3, CD4, CD8, Eosinophils, DCs, and Mast Cells) by Parameter, Skin Layer, Lesion Status, Treatment and Visit

Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured as % Out of Leukocytes.

Observed Values and Change From Baseline in Peripheral Blood Cell Subsets (FACS Parameters) at Week 12 (Day 85) by Treatment (PD Analysis Set) Measured in Fluorescence Units.

Observed Values From Baseline Through End of Study of Serum Chemkines or Histamine in Peripheral Blood Cells by Parameter, Treatment and Visit

Percentage of Angioedema-free Days Weeks 4 Through 12 by Treatment

Serum Levels of Omalizumab

Skindex-29 by Treatment

Summary Statistics of Observed Values and Absolute Change From Baseline in Specific IgE Against Allergens and Bacterial Antigens by Parameter, Treatment and Visit